[Development and Evaluation of At-211 Labeled Peptides]

Area of Science:

• Nuclear medicine
• Radiochemistry
• Oncology

Background:

• Astatine-211 (²¹¹At) is a promising alpha-emitter for targeted alpha therapy (TAT).
• Its properties allow adaptation of radioiodination techniques for radiotheranostics.
• ²¹¹At's short half-life suits tumor-targeting molecules.

Purpose of the Study:

• To review the development of ²¹¹At-labeled peptides for TAT.
• To highlight the use of arginylglycylaspartic acid (RGD) peptide as a model targeting ligand.

Main Methods:

• Review of existing literature on ²¹¹At radiolabeling techniques.
• Focus on methods applicable to peptide labeling.
• Discussion of RGD peptide as a targeting moiety.

Main Results:

• ²¹¹At labeling is feasible using established radioiodination methods.
• Peptide-based targeting agents can be effectively labeled with ²¹¹At.
• RGD peptides demonstrate potential for ²¹¹At delivery to target sites.

Conclusions:

• ²¹¹At is a viable radionuclide for TAT, offering radiotheranostic potential.
• ²¹¹At-labeled peptides, such as RGD, are promising for targeted cancer therapy.
• Further development is needed to optimize ²¹¹At-based radiopharmaceuticals.